SRX Global and CERO 1236 SPV enter agreement to acquire CERo Therapeutics
SRX Global and CERO 1236, a wholly-owned SPV, entered into a definitive agreement to acquire CERo Therapeutics, an innovative cellular immunotherapy company developing CER 1236 for hematologic malignancies.
Story updates
07:00:07 PM UTC
SquawkNews
SRX Global And CERO 1236, A Wholly-Owned SPV, Enter Into Definitive Agreement To Acquire CERo Therapeutics, An Innovative Cellular Immunotherapy Company Developing CER 1236 For Hematologic Malignancies >SRXH